Current Research Studies

The following are ongoing clinical research studies being conducted at the MRC or at affiliated sites by MRC investigators. If you would like to participate in one of our research studies, please e-mail and indicate which study you are interested in. 


Fate of Fructose Study

The purpose of this NIH-funded study is to determine the mechanism of how fructose consumption contributes to excess fatty acid synthesis and elevations in blood glucose levels following consumption of meals containing fructose. Eligible individuals include healthy adults as well as prediabetic or hyperinsulinemic adults. PI: Jean-Marc Schwarz, PhD. 

To take an online eligibility survey for the study, click here. If your answers indicate you may be eligible, a member of the study team will contact you. Your answers will not be shared with anyone outside the research team.



The GPGV study is a Phase 3 randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacokinetics/pharmacodynamics of tirzepatide in pediatric and adolescent participants with type 2 diabetes that is inadequately controlled with metformin and/or basal insulin. PI: Jay Shubrook, DO and Tami Hendriksz, DO.


A Phase 2 Study of Once Daily LY3502970 Compared with Placebo and Once Weekly Dulaglutide in Participants with Type 2 Diabetes Mellitus (GZGE Study)

The GZGE study is a Phase 2, multicenter, randomized, double-blinded study to compare the safety and efficacy of LY3502970 in volunteers with type 2 diabetes who failed to achieve adequate glycemic control from diet and exercise alone or on a stable dose of metformin. PI: Jay Shubrook, DO. 


Orange Juice and Sugar Intake Study (OASIS) 

This follow-up to the MESA study seeks to compare the effects of sugar-sweetened beverages vs. naturally sweetened beverages (orange juice) in healthy individuals. PI: Kimber Stanhope, PhD (UCD and TUC). 


TrialNET Pathway to Prevention

The Pathway to Prevention program is part of TrialNET, an international network dedicated to the prevention of type 1 diabetes. Pathway to Prevention screens family members of individuals with type 1 diabetes in efforts to predict the onsent of the disease. PI: Jay Shubrook, DO


This Phase III trial tests if the drug, dulaglutide, is effective and safe for treating type 2 diabetes in children and teens. PI: Jay Shubrook, DO.


Recently Completed Studies:  

Reducing Inflammation with Osteopathic Treatment (RIOT)

The aim of the RIOT trial is to determine whether osteopathic manipulative treatment (OMT) will blunt changes in serum cytokines that are markers of inflammation and adipokines in asymptomatic subjects. PI: Melissa Pearce, DO. 

Metabolic Effects of Sugar/Aspartame (MESA) Study

In collaboration with UC Davis, the NIH-funded MESA study seeks to determine the effects of excess sugar intake on metabolism when consumed in an energy-balanced diet. Procedures performed at the MRC include stable isotope infusions, body composition measurement by dual-energy X-ray absorptiometry (DXA), and the hyperinsulinemic, euglycemic clamp. PI: Jean-Marc Schwarz, PhD (TUC) and Peter Havel, DVM (UCD).

Eli Lilly SURPASS-4 Study

The purpose of the study is to compare the efficacy and safety of tirzepatide once weekly versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk. Eligible subjects include adults with Type 2 Diabetes who are on stable treatment with unchanged dose of 1 to 3 oral antihyperglycemic drugs. PI: Jay Shubrook, DO

Cardiovascular Inflammation Reduction Trial (CIRT)

The primary aim of the Cardiovascular Inflammation Reduction Trial (CiRT) is to directly test the inflammatory hypothesis of atherothrombosis by evaluating whether or not low-dose methotrexate will reduce rates of myocardial infarction, stroke, and cardiovascular death among stable coronary artery disease patients with type 2 diabetes or metabolic syndrome.

Takeda Phase 3 Alogliptin Pediatric Study

The purpose of this study is to evaluate the efficacy and safety of alogliptin when administered as a monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, in 10-17 year olds with type 2 diabetes mellitus.


Home page side nav Res svcs side nav Studies side nav Contact side nav